SCHEMBL149342

SCHEMBL149342

CSCCN[C@@H](CCSC)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RNPEP Q9H4A4 1/20 0.48
LMNA P02545 2/20 0.47
PKM P14618 1/20 0.47
ALDH1A1 P00352 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.43
FOLH1 Q04609 1/20 0.42
CA2 P00918 2/20 0.42
MAPK1 P28482 1/20 0.42
CA1 P00915 1/20 0.42
FNTA P49354 2/20 0.42
FNTB P49356 2/20 0.42
PGGT1B P53609 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8755755 1.00 RNPEP (0.48) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL2118366 0.89 RNPEP (0.46) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL2118362 0.89 RNPEP (0.46) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL4450408 0.89 RNPEP (0.46) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL25555058 0.87 LMNA (0.48) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL28008087 0.87 GGT1 (0.57) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL2494626 0.87 GGT1 (0.57) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL29428966 0.85 NOD1 (0.47) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL17004002 0.85 LMNA (0.43) RNPEPLMNAPKMALDH1A1NPSR1
SCHEMBL27750256 0.85 NOD1 (0.47) RNPEPLMNAPKMALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US claimed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO claimed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP claimed
CN-117098544-A Diterpenoid compounds acting on Protein Kinase C (PKC) K-GEN治疗股份有限公司 2023-11-21 CN claimed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US claimed
WO-2022204327-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN, INC. (US) 2022-09-29 WO claimed
EP-4041268-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen, Inc. (US) 2022-08-17 EP claimed
CN-114786697-A Diterpenoids acting on Protein Kinase C (PKC) K-GEN股份有限公司 2022-07-22 CN claimed
US-20100029646-A1 PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS TOPO TARGET A/S (DK) 2010-02-04 US claimed
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES VICTORIA LINK LIMITED (NZ) 2024-08-29 US disclosed
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
EP-4351581-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES Victoria Link Limited (NZ) 2024-04-17 EP disclosed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO disclosed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP disclosed
US-20100273789-A1 AMINOACYL PRODRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-28 US disclosed
US-20100029646-A1 PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS TOPO TARGET A/S (DK) 2010-02-04 US disclosed
US-7230017-B2 Dihydropyridinone derivatives BAYER HEALTHCARE AG (DE) 2007-06-12 US disclosed
US-20060100207-A1 Dihydropyridinone derivatives BAYER HEALTHCARE AG (DE) 2006-05-11 US disclosed
EP-0765307-A1 N ALPHA-2-(4-NITROPHENULSULFONYL)ETHOXYCARBONYL-AMINO ACIDS Hyundai Pharm. Ind. Co., Ltd. (KR) 1997-04-02 EP disclosed
WO-1996025394-A1 Nα-2-(4-NITROPHENULSULFONYL)ETHOXYCARBONYL-AMINO ACIDS HYUNDAI PHARM. IND. CO., LTD. (KR) 1996-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100207-A1 Dihydropyridinone derivatives TNNI3, DHPS, TNNT2 RNPEP 2516/4885LMNA 2783/4885PKM 435/4885
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES EBNA1BP2, RPL35, RPL7 RNPEP 747/4885LMNA 1866/4885PKM 2665/4885
US-20100273789-A1 AMINOACYL PRODRUGS AADAC, DNPEP, AADAT RNPEP 124/4885LMNA 1701/4885PKM 1500/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB RNPEP 4042/4885LMNA 2077/4885PKM 882/4885
US-20100029646-A1 PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS IDO1, IDO2, TDO2 RNPEP 1264/4885LMNA 3473/4885PKM 2214/4885
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCB, PRKCI RNPEP 4200/4885LMNA 2312/4885PKM 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.